Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has filed a provisional patent application (“PPA”) with the United States Patent and Trademark Office (“USPTO”). The patent, which was filed on Oct. 8, 2021, covers CMND’s proprietary, novel methods of drug-assisted psychotherapy. According to the company, drug-assisted psychotherapy combines drug and psychological treatments designed to create a superior outcome when used together, including an improved patient-therapist relationship and increased flexibility in the patient’s mind, which allows a patient to explore new methods of treatment. “This filing is another marker in our commitment to build value by establishing a best-in-class IP portfolio to include novel molecules, delivery mechanisms, processes and protocols,” said Clearmind Medicine CEO Adi Zuloff-Shani, PhD, in the press release. “These discoveries reflect the dedication, innovation and creativity at the heart of our research and development team, and position us to pursue the substantial market opportunity in the field of psychedelic-based medicine.”
To view the full press release, visit https://nnw.fm/ts416
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, Binge Behavior Regulators, has been granted in the United States, Europe, China and India, with pending divisional applications in Europe and the U.S. The second, Alcohol Beverage Substitute, has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. To learn more about the company, please visit www.ClearmindMedicine.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
